News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma appoints advisor for the commercialization of PledOx®

May 6, 2013

PledPharma AB
Company Announcement

PledPharma appoints advisor for the commercialization of PledOx®

PledPharma intends to out-licence oncology compound PledOx starting in 2013 for
further development and commercialization. PledPharma has contracted with IMS
Consulting Group (IMSCG) as a strategic advisor to facilitate the process. 

Stockholm, 2013-05-06 08:30 CEST (GLOBE NEWSWIRE) -- PledPharma is looking to
license PledOx to a major pharmaceutical company with a proven commitment to
oncology.  The deal structure is expected to include an upfront payment at
signing and at key development milestones, followed by sales-based royalties. 

“PledOx is a powerful compound with the potential to accelerate the oncology
strategy of a major pharma company,” says Jacques Näsström, CEO PledPharma.
“IMSCG has a strong history of catalyzing successful transactions, and we are
looking forward to working with our partner,” ends Jacques. 

“We see great potential in PledOx’s ability to reduce serious side effects
during cancer treatment,” said Dan Ross, Senior Principal, IMS Consulting
Group. “Our team will work closely with PledPharma to identify the ideal
commercialization partner to ensure that this important therapy becomes
accessible to the right patients,” ends Dan, IMSCG. 

PledOx’s ability to reduce the serious side effects of chemotherapy treatment
with FOLFOX (a combination of FOLinate, 5-FU and OXaliplatin) in patients with
metastatic (spread) colorectal cancer is currently being studied in the Phase
IIb study PLIANT (for details, see ). Results from the
study are expected in mid-2014. 

For further information please contact:
Jacques Näsström, CEO

 +46 737 130979

About IMS Consulting Group

The IMS Consulting Group within IMS Health provides specialized, evidence-based
advisory services on critical business issues for life sciences organizations.
With a global presence and local expertise across six continents, it provides
strategic advice and transformational insights into healthcare dynamics in
critical areas that include pricing & market access, marketing, and product,
portfolio and geographic investment decisions. IMS Consulting Group also serves
as a business development advisor to life sciences clients on the buy-side and
sell-side of transactions. 

About IMS Health

IMS Health is a leading worldwide provider of information, technology, and
services dedicated to making healthcare perform better. The company’s expert
resources draw on data from nearly 100,000 suppliers, and on insights from 39
billion healthcare transactions processed annually, to serve more than 5,000
healthcare clients globally. Customers include pharmaceutical, medical device
and consumer health manufacturers and distributors, providers, payers,
government agencies, policymakers, researchers and the financial community. 

About PledPharma

PledPharma is a Swedish specialty pharma company that develops PledOx® for
prevention of severe chemotherapy-induced side effects in cancer patients. Due
to these side effects optimal treatment cannot be carried out. The current
market for supportive cancer care is some SEK 72 billion. PledOx protects
normal cells against oxidative stress. It belongs to a group of compounds named
lowMEM (low Molecular Enzyme Mimetics), and mimics the enzyme Manganese
SuperOxide Distmutase (MnSOD) – the most important endogenous cellular
protectant against devastating oxidative stress. Oxidative stress is a
condition caused by harmful oxygen/nitrogen molecules, e.g., as a result of
chemotherapy treatment. The company is also evaluating opportunities of using
PLED substances in other diseases. PledPharma (STO:PLED) is listed on NASDAQ
OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For
further information, please visit



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10